Research and Markets has announced the addition of the "Rhino-Conjunctivitis - Pipeline Review, H1 2016" drug pipelines to their offering.
Rhino-Conjunctivitis pipeline therapeutics constitutes close to 24 molecules. which approximately 24 molecules are developed by Companies.
Furthermore, the publisher says; Rhino-Conjunctivitis Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.
The report 'Rhino-Conjunctivitis Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies
Universities.
It also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 3, 7, 10, 3 and 1 respectively.
Key Topics Covered:
- Introduction
- Rhino-Conjunctivitis Overview
- Therapeutics Development
- Pipeline Products for Rhino-Conjunctivitis Overview
- Pipeline Products for Rhino-Conjunctivitis Comparative Analysis
- Rhino-Conjunctivitis Therapeutics under Development by Companies
- Rhino-Conjunctivitis Therapeutics under Investigation by Universities/Institutes
- Rhino-Conjunctivitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Rhino-Conjunctivitis Products under Development by Companies
- Rhino-Conjunctivitis Products under Investigation by Universities/Institutes
- Rhino-Conjunctivitis Companies Involved in Therapeutics Development
- ALK-Abello A/S
- Allergy Therapeutics Plc
- ASIT biotech s.a.
- Bial Portela Ca, S.A.
- Circassia Pharmaceuticals Plc
- Faes Farma, S.A.
- Griffin Discoveries BV
- HAL Allergy BV
- Immunomic Therapeutics, Inc.
- Laboratorios LETI S.L.
- Oxagen Limited
- Roxall Medizin GmbH
- Stallergenes SAS
For more information visit http://www.researchandmarkets.com/research/l3mtxx/rhinoconjunctivit
View source version on businesswire.com: http://www.businesswire.com/news/home/20160712006161/en/
Contacts:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716